Politics 

Trump administration pushes back on report that it declined to buy more Pfizer vaccine doses – CBS News

The White Home is pushing back on a New York Times report that it had the chance to buy far more doses of the Pfizer COVID-19 vaccine this summer season however declined, which means Pfizer may not find a way to present more than the preliminary deal till June.

A senior administration official informed reporters Monday that the New York Occasions story is “false.” The Trump administration, the official mentioned, is “in the course of negotiations proper now and may’t speak publicly about it,” however they really feel “completely assured” that each American who desires a vaccine will get one. The official mentioned the preliminary settlement with Pfizer to buy 100 million doses was introduced in July, and that anybody wanting to promote extra doses at that level “was simply not going to get the federal government’s cash.”

In its July press release saying the acquisition settlement for 100 million doses of the vaccine, Pfizer mentioned the federal authorities had agreed to buy 100 million doses, and mentioned the “U.S. authorities can also purchase up to a further 500 million doses.”

In an announcement to CBS News, Pfizer mentioned Monday that any extra doses past the 100 million agreed upon will want to be dealt with individually.

“The U.S. authorities positioned an preliminary order of 100 million doses for Pfizer-BioNTech’s COVID-19 vaccine, and Pfizer is prepared to start delivery preliminary doses quickly after receiving an Emergency Use Authorization from the FDA,” the corporate mentioned. “Any extra doses past the 100 million are topic to a separate and mutually-acceptable settlement. The corporate will not be ready to remark on any confidential discussions that could also be happening with the U.S. authorities.”

Representatives from Pfizer and Moderna is not going to be attending the White Home’s vaccine summit this week.

The primary vaccinations are anticipated to attain susceptible residents and well being care staff this month. The efficacy price for the Pfizer vaccine is over 90%.


U.S. see record COVID infections and hospital…

10:30

Fin Gomez and Arden Farhi contributed to this report.

Related posts

Leave a Comment